American Association for Cancer Research
crc-22-0427-s09.pptx (257.94 kB)

Supplementary Figure 7 from Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers

Download (257.94 kB)
posted on 2023-07-19, 14:20 authored by Taraswi Mitra Ghosh, Suman Mazumder, Joshua Davis, Jyoti Yadav, Ayuba Akinpelu, Ahmed Alnaim, Harish Kumar, Razan Waliagha, Allison E. Church Bird, Soroush Rais-Bahrami, R. Curtis Bird, Panagiotis Mistriotis, Amarjit Mishra, Clayton C. Yates, Amit K. Mitra, Robert D. Arnold

Supplementary Fig. 7 shows Single-Cell transcriptomics; Identifies epithelial to mesenchymal transition (EMT) marker TGFB1 in ARLow/mCRPC/NEPC (PC-3 spheroid CONT-No treatment vs, extended exposure-EE and conventional exposure-CONV). Result showed TGFB1 expression decreases after EE compared to CONV treatment, which indicated EE moderated stemness in ARLow/mCRPC/NEPC. Single-cell RNA sequencing used the droplet sequencing method (10X Genomics). Each dot represents a single cell. t-distributed stochastic neighbor embedding (tSNE) plots showing the comparison between the single-cell clusters as shown.





The utilization of metronomic-like dosing regimens of topotecan alone and in combination with DTX resulted in the suppression of makers associated with EMT and stem-like cell populations in AVPC models. The identification of molecular signatures and their potential to serve as novel biomarkers for monitoring treatment efficacy and disease progression response to treatment efficacy and disease progression were achieved using bulk RNA-seq and single-cell-omics methodologies.